Related Experiment Video

Updated: Apr 7, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

Pierre Combe1, Eleonore de Guillebon1, Constance Thibault2

  • 1Department of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France ; INSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France.

Oncoimmunology
|July 9, 2015
PubMed

Insights

No new immunotherapies for renal cell cancer (RCC) have been approved recently. Current research explores combining vaccines with anti-angiogenic agents to overcome tumor immunosuppression and improve treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Renal cell cancer (RCC) treatment has seen limited immunotherapy advancements since recombinant cytokines.
  • Previous RCC vaccine trials, while unsuccessful, identified potential predictive biomarkers for immune response.

Approach:

  • Investigating combination therapies to target the immunosuppressive tumor microenvironment in RCC.
  • Utilizing immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1/PD-L1) and anti-angiogenic agents for metastatic RCC.

Key Points:

  • Therapeutic vaccines (e.g., IMA-901, AGS-003) are being evaluated in combination with anti-angiogenic agents.
  • Focus on overcoming tumor-induced immunosuppression via regulatory T-cells, myeloid suppressor cells, and cytokines.
  • Exploiting synergy between novel immunotherapies and established anti-angiogenic treatments.

Conclusions:

  • Combination strategies hold promise for enhancing RCC immunotherapy efficacy.
  • Targeting the tumor microenvironment is crucial for advancing RCC treatment.
  • Ongoing Phase III trials aim to validate synergistic effects for improved patient outcomes.
Keywords:
AGS-003CAIXIMA-901Memorial Sloan Kettering Cancer Center; NKVon Hippel Landauanti-angiogenic agentcarbonic anhydrase IX; ccRCCcheckpoint inhibitorclear cell renal cell carcinoma; CIKcytokine induced killer; CTLcytotoxic T-lymphocyte-associated protein 4; DCcytotoxic T-lymphocyte; CTLA-4dendritic cell; GM-CSFgranulocyte macrophage colony-stimulating factor; HGFheat shock protein; IFNhepatocyte growth factor; HLAhuman leukocyte antigen; HSPinterferon; ILinterleukin; KIRkiller immunoglobin-like receptor; MDRmajor histocompatibility complex; MSKCCmultidrug resistance protein; MDSCmyeloid derived suppressor cell; MHCnatural killer; ORRoverall response rate; OSperipheral blood mononuclear cell; PD-1phosphatase and tensin homolog; TAAprogrammed cell death ligand 1; PTENprogrammed cell death protein 1; PD-L1regulatory T-cell; TUMAPrenal cell carcinomatherapeutic vaccinetoll-like receptor; Tregtumor infiltrating lymphocyte; TLRtumor-associated antigen; TILtumor-associated peptide; VEGFvascular endothelial growth factor; VHLverall survival; PBMC

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K